Imunon (NASDAQ:IMNN – Get Free Report) and Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Imunon and Artiva Biotherapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Imunon | 1 | 0 | 1 | 0 | 2.00 |
| Artiva Biotherapeutics | 1 | 0 | 4 | 1 | 2.83 |
Imunon presently has a consensus price target of $10.00, indicating a potential upside of 449.45%. Artiva Biotherapeutics has a consensus price target of $39.00, indicating a potential upside of 297.15%. Given Imunon’s higher possible upside, equities analysts plainly believe Imunon is more favorable than Artiva Biotherapeutics.
Risk and Volatility
Profitability
This table compares Imunon and Artiva Biotherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Imunon | N/A | -341.23% | -153.79% |
| Artiva Biotherapeutics | N/A | -73.15% | -62.74% |
Earnings and Valuation
This table compares Imunon and Artiva Biotherapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Imunon | N/A | N/A | -$14.49 million | ($5.16) | -0.35 |
| Artiva Biotherapeutics | $250,000.00 | 971.00 | -$83.86 million | ($3.54) | -2.77 |
Imunon has higher earnings, but lower revenue than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
4.5% of Imunon shares are held by institutional investors. 2.8% of Imunon shares are held by company insiders. Comparatively, 21.4% of Artiva Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Artiva Biotherapeutics beats Imunon on 9 of the 13 factors compared between the two stocks.
About Imunon
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon’s DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
About Artiva Biotherapeutics
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.
